Guggenheim reaffirms top pick in Biotech after Q3 results

Guggenheim analyst Yatin Suneja has reiterated Denali Therapeutics Inc (NASDAQ:DNLI) as a top pick following the company's third-quarter results, maintaining a Buy rating with a $200 price target. The analyst views the biotech firm as one of the most attractive small- to mid-cap immunology platforms positioned to deliver long-term value.

Suneja highlighted several key takeaways from the third-quarter 2026 results. The Phase III CAPTIVATE study of claseprubart, an active C1s inhibitor, in chronic inflammatory demyelinating polyneuropathy (CIDP) continues to progress. Part A of the study is now projected to require fewer than 200 participants to randomize 128 responders into Part B. Management characterized this projection as conservative and noted that the response rate is keeping up with the interim analysis. The analyst estimates the responder rate across Part A will likely hold at approximately 70%, requiring roughly 185 patients. Part A top-line results are expected by year-end 2027, with Part B results anticipated by year-end 2028.

The Phase II MoMeNtum study in multifocal motor neuropathy (MMN), which enrolled 46 patients, remains on track for December 2026 top-line results. Suneja views this as a relatively low-risk catalyst, believing a favorable trend in grip strength would be sufficient to advance into Phase III, planned to initiate in 2027.

On the pipeline front, DNTH212 preliminary data from Part A of the Phase I study in China are expected in first-quarter 2027, while DNTH312, a claseprubart plus TACI bifunctional, remains on track to be Phase I-ready by year-end 2027.

Denali reported a third-quarter 2026 net loss of $46.6 million, or $0.81 per share. Research and development expenses totaled $45.6 million, while general and administrative expenses were $14.1 million. The company ended the quarter with approximately $1.2 billion in cash, providing runway into 2030. Suneja views claseprubart as a greater than $5 billion pipeline-in-a-product opportunity across generalized myasthenia gravis, CIDP, and MMN.